Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Junichi Yamamoto; Takumi Ito; Yuki Yamaguchi; Hiroshi Handa

doi:10.1039/d2cs00116k

Home SearchPaper Details

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

Royal Society of Chemistry (2022) • Volume 51, Issue 15, Pages 6234-6250

PDF Available

Abstract

Thalidomide and its derivatives are the only protein degraders currently used in clinical practice. This tutorial review provides an overview of the mechanism of action of thalidomide-based degraders and their future perspectives.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1039/d2cs00116k

Language

English

Topic

Protein Degradation and Inhibitors

Keywords

Thalidomide, Action (physics), Mechanism (biology), Computer science, Computational biology, Chemistry, Biology, Medicine, Philosophy, Epistemology, Physics, Internal medicine

Published

January 1, 2022

Citations

121 citations

FWCI

15.38

External Resources

DOI Link OpenAlex

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Revolutionizing healthcare: the role of artificial intelligence in clinical practice

The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.

Cargo Recognition in Clathrin-Mediated Endocytosis

Suggested Papers

Suggested Papers

Revolutionizing healthcare: the role of artificial intelligence in clinical practice

The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.

Cargo Recognition in Clathrin-Mediated Endocytosis